Added value of adjuvant chemotherapy in patients with node-positive pT1-2 colon cancer: a national SNAPSHOT analysis
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag171 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 13.05.2026. Verfasst von Julia Hanevelt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Isala, Zwolle, 8025, The Netherlands. Hauptthemen laut MEDLINE: Colonic Neoplasms, Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with node-positive colon carcinoma commonly receive adjuvant chemotherapy, regardless the tumor’s T-stage. However, early-stage tumors (pT1-2 CC) are largely underrepresented in landmark studies supporting this treatment. This study evaluates the application of adjuvant chemotherapy in those patients based on daily practice. Patients and methods Patients who underwent surgery for either pT1- or pT2-CC were identified from the nationwide SNAPSHOT database and stratified by age (<75 or ≥75 years). Competing risk regression and (cause-specific) Cox proportional hazard models identified factors associated with 5-year cumulative incidence of recurrence and overall survival (OS), respectively.
Results
Lymph node metastases were found in 381 out of 2,312 (16.5%) patients, of whom 275 (72.2%) received adjuvant chemotherapy. The cumulative incidence of recurrence was 0.09 (95% CI 0.06-0.12) and 0.18 (95% CI 0.11-0.27) in patients who did or did not receive adjuvant chemotherapy, respectively (P = .007). In patients under 75, adjuvant chemotherapy was associated with significantly higher OS (91.3% vs 68.1%, P < .001). Corresponding OS probabilities in elderly patients (≥75 years) were 84.5% vs 55.1%, P = .003. After adjusting for confounding, this difference remained only significant in patients under 75: HRadj 0.5, 95% CI 0.1-0.7 and HRadj 0.5, 95% CI 0.2-1.3, respectively. The recurrence rate was not significantly different between patients receiving capecitabine/oxaliplatin (CapOx) and those on Capecitabine monotherapy (CIF 0.09, 95% CI 0.06-0.14 vs 0.05, 95% CI 0.01-0.16, P = .49).
Conclusion
Adjuvant chemotherapy is associated with reduced risk of recurrence in patients with node-positive pT1-2 CC. Advantages on OS could not be demonstrated in elderly pT1-2N1-2 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Isala, Zwolle, 8025, The Netherlands.
- Department of Medical Oncology, Isala, Zwolle, 8025, The Netherlands.
- Department of Surgery, Isala, Zwolle, 8025, The Netherlands.
- Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, 3062, The Netherlands.
- Department of Epidemiology & Statistics, Isala, 8025, The Netherlands.
- Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU), Utrecht, 3584, The Netherlands.
ORCID-Profile: Julia Hanevelt
Förderung
- Dutch Cancer Society
Zitieren
APA
Hanevelt, J., de Groot, J. W. B., Rademaker, E., Zamaray, B., Brohet, R. M., Moons, L. M. G., Vleggaar, F. P., Consten, E. C. J., Tanis, P. J., de Vos tot Nederveen Cappel, W. H., van Westreenen, H. L., & Dutch Snapshot Research Group (DSRG), Dutch Complex Colon Cancer Initiative (DCCCI) and Collaborators Snapshot Registry (2026). Added value of adjuvant chemotherapy in patients with node-positive pT1-2 colon cancer: a national SNAPSHOT analysis. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag171
Vancouver
Hanevelt J, de Groot JWB, Rademaker E, Zamaray B, Brohet RM, Moons LMG, et al. Added value of adjuvant chemotherapy in patients with node-positive pT1-2 colon cancer: a national SNAPSHOT analysis. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag171
BibTeX
@article{Hanevelt2026,
author = {Hanevelt, Julia and de Groot, Jan W B and Rademaker, Eva and Zamaray, Bobby and Brohet, Richard M and Moons, Leon M G and Vleggaar, Frank P and Consten, Esther C J and Tanis, Pieter J and de Vos tot Nederveen Cappel, Wouter H and van Westreenen, Henderik L and Dutch Snapshot Research Group (DSRG), Dutch Complex Colon Cancer Initiative (DCCCI) and Collaborators Snapshot Registry, Dutch Snapshot Research Group (DSRG), Dutch Complex Colon Cancer Initiative (DCCCI) and Collaborators Snapshot Registry},
title = {Added value of adjuvant chemotherapy in patients with node-positive pT1-2 colon cancer: a national SNAPSHOT analysis},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag171}
}
EUVIMED